Patents by Inventor Tongtong Xue

Tongtong Xue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PDL-1 ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
    Publication number: 20200010570
    Abstract: The present invention belongs to the field of tumor therapy and molecular immunology, and relates to a PDL-1 antibody, a pharmaceutical composition thereof and use thereof. In particular, the present invention relates to a PDL-1 monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody has a heavy chain variable region comprising CDRs as set forth in SEQ ID NOs: 15-17; and/or has a light chain variable region comprising CDRs as set forth in SEQ ID NOs: 18-20. The monoclonal antibody of the present invention can bind to PDL-1 specifically, and specifically remove immunosuppressive function of PDL-1 and activate T lymphocytes.
    Type: Application
    Filed: July 19, 2019
    Publication date: January 9, 2020
    Inventors: Baiyong Li, Tongtong Xue, Yu Xia, Zhongmin Maxwell Wang, Liang Xiao, Lichun Wang, Jingyi Wang
  • PDL-1 antibody, pharmaceutical composition thereof, and uses thereof
    Patent number: 10465014
    Abstract: The present invention belongs to the field of tumor therapy and molecular immunology, and relates to a PDL-1 antibody, a pharmaceutical composition thereof and use thereof. In particular, the present invention relates to a PDL-1 monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody has a heavy chain variable region comprising CDRs as set forth in SEQ ID NOs: 15-17; and/or has a light chain variable region comprising CDRs as set forth in SEQ ID NOs: 18-20. The monoclonal antibody of the present invention can bind to PDL-1 specifically, and specifically remove immunosuppressive function of PDL-1 and activate T lymphocytes.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: November 5, 2019
    Assignee: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Baiyong Li, Tongtong Xue, Yu Xia, Zhongmin Maxwell Wang, Liang Xiao, Lichun Wang, Jingyi Wang
  • ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
    Publication number: 20190076438
    Abstract: The present invention provides an anti-ErbB2 antibody-drug conjugate, a composition comprising the conjugate, a method for preparing the conjugate, use of the conjugate.
    Type: Application
    Filed: November 22, 2016
    Publication date: March 14, 2019
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Tongtong XUE, Zhenwei MIAO, Jing WANG, Gang CHEN, Yan QING, Tong ZHU, Liang XIAO, Hong ZHANG, Qiuyan YANG, Dylan Dalun DENG, Liping LIU, Hong ZENG, Li YIN, Qifeng SHI, Hongmei SONG, Xi ZHAO, Lichun WANG, Jingyi WANG
  • PDL-1 ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
    Publication number: 20180305464
    Abstract: The present invention belongs to the field of tumor therapy and molecular immunology, and relates to a PDL-1 antibody, a pharmaceutical composition thereof and use thereof. In particular, the present invention relates to a PDL-1 monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody has a heavy chain variable region comprising CDRs as set forth in SEQ ID NOs: 15-17; and/or has a light chain variable region comprising CDRs as set forth in SEQ ID NOs: 18-20. The monoclonal antibody of the present invention can bind to PDL-1 specifically, and specifically remove immunosuppressive function of PDL-1 and activate T lymphocytes.
    Type: Application
    Filed: March 2, 2017
    Publication date: October 25, 2018
    Inventors: Baiyong Li, Tongtong Xue, Yu Xia, Zhongmin Maxwell Wang, Liang Xiao, Lichun Wang, Jingyi Wang